123 related articles for article (PubMed ID: 30001848)
1. Application of botulinum toxin in Horner's muscle for the treatment of dry eye.
Diaz AL; Chaparro TA; Tello A; Coy H; Frederick GA; Parra MM
Arch Soc Esp Oftalmol (Engl Ed); 2018 Dec; 93(12):617-620. PubMed ID: 30001848
[TBL] [Abstract][Full Text] [Related]
2. Effect of eyelid botulinum toxin injection on lacrimal drainage.
Sahlin S; Chen E; Kaugesaar T; Almqvist H; Kjellberg K; Lennerstrand G
Am J Ophthalmol; 2000 Apr; 129(4):481-6. PubMed ID: 10764857
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
Horwath-Winter J; Bergloeff J; Floegel I; Haller-Schober EM; Schmut O
Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
[TBL] [Abstract][Full Text] [Related]
4. Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids.
Arat YO; Yen MT
Ophthalmic Plast Reconstr Surg; 2007; 23(1):22-4. PubMed ID: 17237684
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type a injection for lateral canthal rhytids : effect on tear film stability and tear production.
Ho MC; Hsu WC; Hsieh YT
JAMA Ophthalmol; 2014 Mar; 132(3):332-7. PubMed ID: 24385079
[TBL] [Abstract][Full Text] [Related]
6. Eyelid botulinum toxin injections for the dry eye.
Sahlin S; Linderoth R
Dev Ophthalmol; 2008; 41():187-192. PubMed ID: 18453769
[TBL] [Abstract][Full Text] [Related]
7. Paralysis of the orbicularis muscle of the eye using botulinum toxin type A in the treatment for dry eye.
Serna-Ojeda JC; Nava-Castaneda A
Acta Ophthalmol; 2017 Mar; 95(2):e132-e137. PubMed ID: 27350144
[TBL] [Abstract][Full Text] [Related]
8. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
Park DI; Shin HM; Lee SY; Lew H
Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
[TBL] [Abstract][Full Text] [Related]
9. Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study.
Pellegrini M; Schiavi C; Taroni L; Sebastiani S; Bernabei F; Roda M; Moscardelli F; Giannaccare G
Indian J Ophthalmol; 2019 Sep; 67(9):1405-1409. PubMed ID: 31436182
[TBL] [Abstract][Full Text] [Related]
10. Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines.
Choi MG; Yeo JH; Kang JW; Chun YS; Lee JK; Kim JC
Graefes Arch Clin Exp Ophthalmol; 2019 Feb; 257(2):331-338. PubMed ID: 30552510
[TBL] [Abstract][Full Text] [Related]
11. Ocular Surface Metrics in Blepharospasm Patients After Treatment With Botulinum Toxin Injections.
Yabumoto C; Osaki MH; Osaki T; Gameiro GR; Campos M; Osaki TH
Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):475-478. PubMed ID: 36928309
[TBL] [Abstract][Full Text] [Related]
12. Botulinum Toxin A Injection for the Treatment of Intractable Dry Eye Disease.
Choi EW; Yeom DJ; Jang SY
Medicina (Kaunas); 2021 Mar; 57(3):. PubMed ID: 33800125
[No Abstract] [Full Text] [Related]
13. Botulinum Toxin A for the Treatment of Photophobia and Dry Eye.
Diel RJ; Kroeger ZA; Levitt RC; Sarantopoulos C; Sered H; Martinez-Barrizonte J; Galor A
Ophthalmology; 2018 Jan; 125(1):139-140. PubMed ID: 29110944
[No Abstract] [Full Text] [Related]
14. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection.
Kocabeyoglu S; Sekeroglu HT; Mocan MC; Muz E; Irkec M; Sanac AS
Eur J Ophthalmol; 2014; 24(6):830-4. PubMed ID: 24803156
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
Hosotani Y; Yokoi N; Okamoto M; Ishikawa H; Komuro A; Kato H; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Jan; 64(1):45-53. PubMed ID: 31823132
[TBL] [Abstract][Full Text] [Related]
16. Dry eye syndrome due to botulinum toxin type-A injection: guideline for prevention.
Ozgur OK; Murariu D; Parsa AA; Parsa FD
Hawaii J Med Public Health; 2012 May; 71(5):120-3. PubMed ID: 22737648
[TBL] [Abstract][Full Text] [Related]
17. Photophobia and sensations of dryness in patients with migraine occur independent of baseline tear volume and improve following botulinum toxin A injections.
Diel RJ; Hwang J; Kroeger ZA; Levitt RC; Sarantopoulos CD; Sered H; Felix ER; Martinez-Barrizonte J; Galor A
Br J Ophthalmol; 2019 Aug; 103(8):1024-1029. PubMed ID: 30269099
[TBL] [Abstract][Full Text] [Related]
18. Treatment of symptomatic epiblepharon with Botulinum toxin type A in patients under 2years of age.
de la Fuente Díez Y; Olvera Morales O; Chen López CY; Tovilla Canales JL; Nava Castañeda A
Arch Soc Esp Oftalmol (Engl Ed); 2020 Jan; 95(1):9-14. PubMed ID: 31806264
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the effects of Botulinum Toxin A on tear metrics in patients with hemifacial spasm.
Mali YP; Schultze RL; Wladis EJ
Orbit; 2017 Oct; 36(5):307-310. PubMed ID: 28627956
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin injection for the management of refractory filamentary keratitis.
Gumus K; Lee S; Yen MT; Pflugfelder SC
Arch Ophthalmol; 2012 Apr; 130(4):446-50. PubMed ID: 22491914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
